标题
Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)
作者
关键词
Catalytic spine, Hydrophobic interaction, Protein kinase inhibitor classification, Protein kinase structure, Regulatory spine, Shell residues
出版物
PHARMACOLOGICAL RESEARCH
Volume -, Issue -, Pages 105422
出版商
Elsevier BV
发表日期
2021-01-12
DOI
10.1016/j.phrs.2021.105422
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Colorectal cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Zanubrutinib: First Approval
- (2020) Yahiya Y. Syed DRUGS
- Molecular epidemiology and diagnostics of KRAS mutations in human cancer
- (2020) Jozsef Timar et al. CANCER AND METASTASIS REVIEWS
- KRAS: From undruggable to a druggable Cancer Target
- (2020) Dipesh Uprety et al. CANCER TREATMENT REVIEWS
- Approaches to mitigate the risk of serious adverse reactions in covalent drug design
- (2020) Thomas A. Baillie Expert Opinion on Drug Discovery
- Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
- (2020) Yi-Long Wu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options
- (2020) Simon Peter Gampenrieder et al. Cancer Management and Research
- Incorporating acalabrutinib, a selective next‐generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies
- (2020) Alexey V. Danilov et al. BRITISH JOURNAL OF HAEMATOLOGY
- Management of Waldenström macroglobulinemia in 2020
- (2020) Jorge J. Castillo et al. Hematology-American Society of Hematology Education Program
- A Practical Review of Proteasome Pharmacology
- (2019) Tiffany A. Thibaudeau et al. PHARMACOLOGICAL REVIEWS
- Acalabrutinib for Mantle Cell Lymphoma
- (2019) Thomas E Witzig et al. BLOOD
- Management of adverse effects/toxicity of ibrutinib
- (2019) Semra Paydas CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Targeting ERK1/2 protein-serine/threonine kinases in human cancers
- (2019) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
- (2019) Pawel Robak et al. Drugs in research & development
- Zanubrutinib in B-cell malignancies
- (2019) Manjulika Das LANCET ONCOLOGY
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- (2019) Suresh S. Ramalingam et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Landscape of Atypical and Eukaryotic Protein Kinases
- (2019) Georgi K. Kanev et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder
- (2019) Robert Roskoski PHARMACOLOGICAL RESEARCH
- U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer
- (2018) Harpreet Singh et al. CLINICAL CANCER RESEARCH
- Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation–positive advanced non-small-cell lung cancer
- (2018) S. Morin-Ben Abdallah et al. Current Oncology
- Progress with covalent small-molecule kinase inhibitors
- (2018) Zheng Zhao et al. DRUG DISCOVERY TODAY
- Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations
- (2018) Tony S. Mok et al. JOURNAL OF CLINICAL ONCOLOGY
- EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib
- (2018) Yoshihisa Kobayashi et al. Journal of Thoracic Oncology
- PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials
- (2018) Fabrice Carles et al. MOLECULES
- Kinase inhibitors: the road ahead
- (2018) Fleur M. Ferguson et al. NATURE REVIEWS DRUG DISCOVERY
- Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers
- (2018) Robert Roskoski et al. PHARMACOLOGICAL RESEARCH
- The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease
- (2018) Maximilian Hochmair Targeted Oncology
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Acalabrutinib and its use in treatment of chronic lymphocytic leukemia
- (2018) Yasir Khan et al. Future Oncology
- Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology
- (2018) Matthias Gehringer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Pharmacological targeting of RAS: Recent success with direct inhibitors
- (2018) John P. O’Bryan PHARMACOLOGICAL RESEARCH
- Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers
- (2017) Robert Roskoski PHARMACOLOGICAL RESEARCH
- ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers
- (2017) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas
- (2017) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Guidelines for preparing color figures for everyone including the colorblind
- (2017) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas
- (2017) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Targeted Covalent Inhibitors for Drug Design
- (2016) Thomas A. Baillie ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
- (2016) Jingjing Wu et al. Journal of Hematology & Oncology
- Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family
- (2016) Jeff B. Smaill et al. JOURNAL OF MEDICINAL CHEMISTRY
- Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions
- (2016) Paul A. Jackson et al. JOURNAL OF MEDICINAL CHEMISTRY
- Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview
- (2016) Peter M. Fischer MEDICINAL RESEARCH REVIEWS
- Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management
- (2015) Morie A. Gertz AMERICAN JOURNAL OF HEMATOLOGY
- FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia
- (2015) R. A. de Claro et al. CLINICAL CANCER RESEARCH
- Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed
- (2015) Yuliana Yosaatmadja et al. JOURNAL OF STRUCTURAL BIOLOGY
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
- (2015) Kenneth S Thress et al. NATURE MEDICINE
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- A historical overview of protein kinases and their targeted small molecule inhibitors
- (2015) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors
- (2015) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?
- (2015) Sai-Hong Ou et al. Drug Design Development and Therapy
- Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
- (2015) Alexandra Canonici et al. Oncotarget
- Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor
- (2014) M. Raymond V. Finlay et al. JOURNAL OF MEDICINAL CHEMISTRY
- Vane’s discovery of the mechanism of action of aspirin changed our understanding of its clinical pharmacology
- (2014) Regina M. Botting Pharmacological Reports
- ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
- (2014) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
- (2013) Qingsong Liu et al. CHEMISTRY & BIOLOGY
- The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders
- (2013) Robert Roskoski Expert Opinion on Drug Discovery
- KLIFS: A Knowledge-Based Structural Database To Navigate Kinase–Ligand Interaction Space
- (2013) Oscar P. J. van Linden et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- The ErbB/HER family of protein-tyrosine kinases and cancer
- (2013) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Proton Pump Inhibitors in Pediatrics
- (2013) Robert M. Ward et al. PEDIATRIC DRUGS
- Deciphering the Structural Basis of Eukaryotic Protein Kinase Regulation
- (2013) Hiruy S. Meharena et al. PLOS BIOLOGY
- New Directions in Targeting Protein Kinases: Focusing Upon True Allosteric and Bivalent Inhibitors
- (2012) Vandana Lamba et al. CURRENT PHARMACEUTICAL DESIGN
- Treatment of Older Patients with Mantle-Cell Lymphoma
- (2012) H.C. Kluin-Nelemans et al. NEW ENGLAND JOURNAL OF MEDICINE
- ERK1/2 MAP kinases: Structure, function, and regulation
- (2012) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition
- (2012) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
- (2012) Ron Bose et al. Cancer Discovery
- The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
- (2011) Arvin C. Dar et al. Annual Review of Biochemistry
- Monoamine Oxidase B Inhibitors for the Treatment of Parkinsonʼs Disease
- (2011) Anthony H.V. Schapira CNS DRUGS
- Cysteine Mapping in Conformationally Distinct Kinase Nucleotide Binding Sites: Application to the Design of Selective Covalent Inhibitors
- (2011) Emeline Leproult et al. JOURNAL OF MEDICINAL CHEMISTRY
- The resurgence of covalent drugs
- (2011) Juswinder Singh et al. NATURE REVIEWS DRUG DISCOVERY
- RAF protein-serine/threonine kinases: Structure and regulation
- (2010) Robert Roskoski BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation
- (2009) Fabio Zuccotto et al. JOURNAL OF MEDICINAL CHEMISTRY
- Lung Cancer
- (2008) Roy S. Herbst et al. NEW ENGLAND JOURNAL OF MEDICINE
- A helix scaffold for the assembly of active protein kinases
- (2008) A. P. Kornev et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
- (2008) C.-H. Yun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started